Comparative Pharmacology
Head-to-head clinical analysis: FLAREX versus INFLAMASE FORTE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLAREX versus INFLAMASE FORTE.
FLAREX vs INFLAMASE FORTE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that inhibits phospholipase A2 activity, reducing arachidonic acid release and subsequent production of prostaglandins and leukotrienes, thereby suppressing ocular inflammation.
Inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
1-2 drops in the conjunctival sac every hour during the day and every 2 hours at night initially; after response, reduce to 1 drop every 4 hours, then 1 drop 3-4 times daily. Ophthalmic suspension.
1-2 tablets (ibuprofen 400mg / pseudoephedrine 60mg) orally every 6 hours as needed; maximum 6 tablets per day.
None Documented
None Documented
Terminal elimination half-life is approximately 1-2 hours (mean 1.3 hours) in adults. Due to rapid clearance, accumulation is minimal with topical ophthalmic dosing, but prolonged use may lead to systemic absorption and slightly extended half-life.
Terminal half-life 36–42 hours in patients with normal renal function; prolonged to 18–26 hours in renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Primarily hepatic metabolism, with inactive metabolites excreted renally (approximately 60-80%) and fecally (20-40%). Less than 5% of unchanged drug appears in urine.
Approximately 95% renal: 90% as unchanged drug via glomerular filtration and tubular secretion, 5% as minor metabolites; 5% fecal via biliary elimination.
Category C
Category C
Ophthalmic Corticosteroid
Ophthalmic Corticosteroid